European beachhead

Epirus thinks reverse merger with Zalicus will open up Europe for biosimilars

European beachhead

Epirus Biopharmaceuticals Inc. hopes its $36 million series B round and reverse merger with Zalicus Inc. (NASDAQ:ZLCS) will enable the biosimilars company to crack the European market.

The combined public company will retain Epirus' name and focus on

Read the full 380 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE